Abstract
This study examines the independent and joint associations of cardiometabolic multimorbidity (CMM) and depression with cognitive function in older adults. Utilizing pooled individual participant data from 14 international cohorts ($N > 30,000$), we found that while CMM and depression do not interact synergistically, their additive effects significantly accelerate cognitive decline. These findings are consistent across global regions and generalize from community to clinical settings, emphasizing the need for integrated management of physical and mental health to preserve cognitive longevity.
Introduction
As the global population ages, dementia has emerged as a primary public health challenge. While researchers have long identified individual risk factors like diabetes or depression, real-world patients rarely present with a single chronic condition. Multimorbidity—the co-occurrence of multiple chronic conditions—is the rule rather than the exception in older age.
This research addresses a critical gap: how physical cardiometabolic clusters (such as hypertension, diabetes, and heart disease) and mental health (depression) work together to influence the brain. Furthermore, the study seeks to determine if these associations hold true across diverse ethnicities and different healthcare settings, ranging from general communities to specialized memory clinics.
Methods
The researchers utilized a pooled individual participant data (IPD) analysis, harmonizing raw data from 14 longitudinal cohorts within the Cohort Studies of Memory in an International Consortium (COSMIC). This approach is more robust than standard meta-analysis as it involves re-analyzing standardized data rather than aggregating published results.
Definitions and Scoring
Two definitions of CMM were tested:
- CMM5: Presence of $\ge$ 2 conditions among hypertension, hyperlipidemia, diabetes, stroke, and heart disease.
- CMM3: Presence of $\ge$ 2 conditions among diabetes, stroke, and heart disease (a stricter definition reflecting higher disease severity).
Global cognition was standardized into z-scores to allow comparison across different neuropsychological tests used globally.
Validation
To ensure generalizability, findings were validated using three external Asian cohorts representing a spectrum of care: the Singapore Epidemiology of Eye Diseases study (Community), a Singapore memory clinic study (Clinical), and the COgnition After STroke (COAST) cohort (Clinical/Post-stroke).
Results
Independent and Additive Effects
A key finding is that CMM and depression are independently associated with cognitive decline. No significant statistical interaction (synergy) was found, meaning depression does not specifically worsen the cognitive impact of diabetes or heart disease. Instead, the joint association is additive; participants with both conditions showed the poorest cognitive performance and the steepest decline over time.
Quantitative Findings
- Cross-sectional: Participants with both CMM5 and depression had significantly lower cognitive z-scores ($\beta = -0.207$) compared to healthy controls.
- Longitudinal: Those with both conditions experienced a faster annual rate of cognitive decline ($\beta = -0.040$).
- Severity: CMM3 was associated with a stronger negative impact on baseline cognition than CMM5, likely reflecting the higher severity of its constituent diseases compared to "silent" risks like hypertension.
Demographic Trends
Interaction analyses suggested that the association between CMM/depression and cognitive decline might be more pronounced in females and in individuals residing in high-income countries (HICs) compared to lower-middle-income countries (LMICs).
Discussion
The consistency of these findings across global regions and clinical settings suggests a fundamental biological relationship between cardiometabolic health, mental health, and neurocognition. The inclusion of metabolic risks like hypertension in the CMM5 definition tripled the observed prevalence of multimorbidity, highlighting the importance of early intervention.
Limitations
The study relies on some self-reported diagnoses, which may lead to underestimation. Additionally, the observational design cannot definitively rule out reverse causation, where early cognitive impairment leads to depressive symptoms. The absence of brain imaging or biomarkers limits the ability to clarify specific underlying pathologies, such as vascular damage versus Alzheimer’s disease.
Conclusion
Future interventions should move away from single-disease models and instead target both cardiometabolic and psychological health simultaneously to protect the aging brain. Integrated care strategies are essential to mitigate the cumulative burden of multimorbidity on cognitive health.
Summary updated